Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →Yahoo Finance
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
4
in the last 3 days
First reported
10 hr. ago
3 outlets since
Countries
3 other outlets reported this story in the last 3 days.
JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210, implying about 33% upside. Analyst Chris Schott…
eBay (EBAY) is heading into its third-quarter earnings report with Wall Street divided over whether live commerce can sustain its growth momentum.
According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.